Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05093881

Enrollment

100

Registered

2021-10-26

Start date

2021-08-24

Completion date

2028-03-31

Last updated

2024-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholic Cirrhosis

Brief summary

This Long-term follow-up is designed to evaluate the safety of patient with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.

Detailed description

To evaluate the safety for 60 months after a single dose of Cellgram-LC in patients with alcoholic liver cirrhosis.

Interventions

BIOLOGICALCellgram-LC

Patients who had administered Cellgram-LC in PMC-P-07 study

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Those who participated in PMC-P-07 clinical trials and received Cellgram-LC 2. Those who voluntarily agreed in writing to participate in this investigation

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Rate of AESI	For 5 years	death, neoplasms or malignancies in tissues or organs, Immune response including exacerbation or new outbreaks of previous autoimmune diseases, Other delayed AE related to Cellgram LC)
Rate of Liver transplant	For 5 years	Liver transplant

Countries

South Korea

Contacts

Primary ContactJIYEOUN JEONG

jyjeong@pharmicell.com82-2-3496-0134

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026